Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K. Gottlieb AB, et al. Among authors: drew j. J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Epub 2018 Apr 13. J Am Acad Dermatol. 2018. PMID: 29660421 Free article. Clinical Trial.
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB. Blauvelt A, et al. Among authors: drew j. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):546-552. doi: 10.1111/jdv.15258. Epub 2018 Oct 14. J Eur Acad Dermatol Venereol. 2019. PMID: 30242918 Free PMC article.
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M, Blauvelt A, Paul C, Sofen H, Węgłowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M. Lebwohl M, et al. Among authors: drew j. J Am Acad Dermatol. 2018 Aug;79(2):266-276.e5. doi: 10.1016/j.jaad.2018.04.013. Epub 2018 Apr 14. J Am Acad Dermatol. 2018. PMID: 29660425 Free article. Clinical Trial.
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, Gopalan R, Simpson EL. Guttman-Yassky E, et al. Among authors: drew j. JAMA Dermatol. 2020 Apr 1;156(4):411-420. doi: 10.1001/jamadermatol.2020.0079. JAMA Dermatol. 2020. PMID: 32101256 Free PMC article. Clinical Trial.
Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, Drew J, Quiring J, Pariser DM. Glaser DA, et al. Among authors: drew j. J Am Acad Dermatol. 2019 Jan;80(1):128-138.e2. doi: 10.1016/j.jaad.2018.07.002. Epub 2018 Jul 10. J Am Acad Dermatol. 2019. PMID: 30003988 Free article. Clinical Trial.
Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Hebert AA, Glaser DA, Green L, Werschler WP, Forsha DW, Drew J, Gopalan R, Pariser DM. Hebert AA, et al. Among authors: drew j. Pediatr Dermatol. 2019 Jan;36(1):89-99. doi: 10.1111/pde.13723. Epub 2018 Nov 19. Pediatr Dermatol. 2019. PMID: 30451318 Free PMC article. Clinical Trial.
Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
Hebert AA, Glaser DA, Green L, Hull C, Cather J, Drew J, Gopalan R, Pariser DM. Hebert AA, et al. Among authors: drew j. Pediatr Dermatol. 2020 May;37(3):490-497. doi: 10.1111/pde.14135. Epub 2020 Mar 8. Pediatr Dermatol. 2020. PMID: 32147881 Free PMC article. Clinical Trial.
497 results